Boxed Warning of HBV Risk Added to Rituxanhttp://www.medpagetoday.com/PublicHealt ... eral/41864
The FDA announced today that rituximab (Rituxan) and ofatumumab (Arzerra) will now carry a boxed warning of the risk for immunosuppression-related reactivation of hepatitis B virus (HBV).
The two agents are anti-CD20-directed monoclonal antibodies used to treat chronic lymphocytic leukemia. Rituximab also is used for non-Hodgkin's lymphoma, rheumatoid arthritis, vasculitis, and other conditions.
Reactivation of HPV can occur ...